The product is useful enough to be explained incorrectly.
The obvious explanation is simple: Healthspan gives advisors better longevity data. That sounds focused, and it is probably enough to open early conversations. It is also too small.
Data is an input. Reports, reminders, assessments, and content are useful parts of the experience, but none of them make Healthspan Wealth a serious enterprise software company on their own. The strategic question is whether Healthspan owns the institutional response that follows the insight.
The buyer is not the individual advisor who wants another clever tool. The buyer is the scaled wealth firm trying to make a high-trust service model repeatable.
That means offices, advisors, family members, compliance boundaries, approved vendors, documents, CRM records, and executive reporting all matter. Those constraints are not implementation noise. They are the buying reason.
The market disappears, then the account gets better.
The adviser universe looks large until it is useful. More than 16,000 adviser firms report AUM, but most are structurally irrelevant for this wedge. They are too small, too owner-led, or too operationally simple to need a firm-controlled transition layer.
Once the target is scaled wealth firms, the market compresses quickly: 556 broad enterprise-adjacent firms, 196 realistic expansion candidates, 92 in the tight SEIA neighborhood, and 39 names worth first review. That is only a problem if Healthspan is a point solution. For enterprise software, it is the point.
Firm count falls as operational value rises.
The right target segment is smaller because the buyer has more offices, employees, household complexity, compliance burden, and workflow variation.
The stack is crowded around the work, not inside it.
The incumbent wealthtech stack is not weak. CRM, planning, documents, portfolio reporting, custody, trading, compliance, and AI notetaking are already served. That is why the opening is attractive.
The missing category is the governed path through those systems. CRM records the relationship. Planning models the money. Documents store artifacts. AI tools summarize conversations. Vendors solve pieces of the family problem. None of them owns the moment when a household signal becomes firm-approved work.
Healthspan should own the transition workflow.
The category is not another app in the stack. It is the operating layer that coordinates signal, trigger, action, routing, completion, and evidence.
Pricing is not a monetization choice. It is a category choice.
If Healthspan is sold as data, the market will price it like a specialty module. That may produce a useful feature business, but it will not create the enterprise company implied by the opportunity.
At 20% penetration of the 556-firm broad universe, a $50,000 ACV product produces only $5.6 million of ARR. At $250,000 ACV, the same market produces $27.8 million. At $500,000 ACV, it produces $55.6 million. The hard question is not "What should we charge?" It is "What must the product become for a scaled firm to believe this is infrastructure?"
The same market supports very different companies.
Enterprise ACV requires enterprise substance: roles, controls, CRM paths, vendor governance, evidence, and reporting.
The first customer is not custom work. It is the architecture.
The first scaled rollout should not be rushed through as implementation work. It is the raw material of the product. Salesforce constraints, security review, SSO expectations, advisor adoption, contact-only family access, approved resources, vendor governance, document requests, AI drafts, and evidence logs are not side quests.
Those constraints are what the next enterprise buyer will evaluate. Lead with enough service to understand the institution, then turn each recurring constraint into a product surface. That is how longevity becomes the wedge into high-trust household service infrastructure.
The next twelve months should prove repeatability, not breadth.
Healthspan should not chase every firm or every life event. The near-term job is to prove that a scaled wealth firm can deploy a standard of care, measure it, and repeat it in a second institution without re-inventing the product.
Package the deployment machine before broad market expansion.
The sequencing should convert first-customer knowledge into reusable enterprise architecture.
Closing thesis
Healthspan Wealth should become the firm-controlled operating layer for the moments when wealthy households need coordinated guidance across aging, health, estate, care, insurance, family, tax, and service-provider decisions. The firm owns the standard of care. The advisor owns the relationship. Healthspan owns the sequence that makes both scalable.